OmniLife Robotic Tissue Balancer Cleared

FDA has cleared an OmniLife Science 510(k) for its proprietary robotic tissue balancing device for use with the company’s OmniBotics robotic-assisted total knee replacement technology platform. The device is intended to provide surgeons with a quantitative tool to actively manage the soft tissue envelope with real-time feedback, according to the company. “When combined with the accuracy of alignment and bone cuts provided by the OmniBotics system, the result is a completely customized procedure from both a skeletal perspective as well as a soft tissue perspective,” it says.

The OmniBotics system performs knee implant placement using robotics driven by Omni’s proprietary ART software, Omni says. It also eliminates the need for preoperative CT scans or x-rays. “Intraoperative adjustments are easily made, and the precise alignment of the implant may lead to a more rapid recovery and a more natural feeling total knee replacement,” it adds.